Hepatocellular carcinoma in non-alcohol fatty liver disease – changing trends and specific challenges

References

• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576.
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. results from the global burden of disease study 2015 global burden of disease liver cancer collaboration. JAMA Oncol. 2017;3(12):1683–1691.
   PubMed Web of Science ®Google Scholar
• Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61(1):191–199.
   PubMed Web of Science ®Google Scholar
• Petrick JL, Kelly SP, Altekruse SF, et al. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol. 2016;34(15):1787–1794.
   PubMed Web of Science ®Google Scholar
• Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47(Suppl):S2–S6.
   PubMed Web of Science ®Google Scholar
• Ghouri Y, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.
   PubMedGoogle Scholar
• SEER Cancer Statistics Factsheets: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute. 2014. [cited 2019 March]. Available from: http://www.seer.cancer.gov/statfacts/html/livibd.html
   Google Scholar
• Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92(10):1862–1868.
   PubMed Web of Science ®Google Scholar
• Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60(1):110–117.
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42(6):563–570.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–555.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188–2195.
   PubMed Web of Science ®Google Scholar
• Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54(4):367–376.
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–640.
   PubMed Web of Science ®Google Scholar
• White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342–1359.e2.
   PubMed Web of Science ®Google Scholar
• Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24(2):248–254.
   PubMed Web of Science ®Google Scholar
• Hernandez-Alejandro R, Croome KP, Drage M, et al. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol. 2012;18(31):4145–4149.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828–1837.e2.
   PubMed Web of Science ®Google Scholar
• Akuta N, Kawamura Y, Arase Y, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol. 2018;18(1):165.
   PubMed Web of Science ®Google Scholar
• Tokushige K, Hashimoto E, Kodama K. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan. J Gastroenterol Hepatol. 2013;28(Suppl 4):88–92.
   PubMed Web of Science ®Google Scholar
• Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014;61(1):75–81.
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Arase Y, Ikeda K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107(2):253–261.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639–1648.
   PubMed Web of Science ®Google Scholar
• Calle E, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang X, Wang J, et al. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012;48(14):2137–2145.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328.
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809.
   PubMed Web of Science ®Google Scholar
• Grohmann M, Wiede F, Dodd GT, et al. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018;175(5):1289–1306.e20.
   PubMed Web of Science ®Google Scholar
• Bruschi FV, Tardelli M, Claudel T, et al. PNPLA3 expression and its impact on the liver: current perspectives. Hepat Med. 2017;9:55–66.
   PubMed Web of Science ®Google Scholar
• He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285(9):6706–6715.
   PubMed Web of Science ®Google Scholar
• Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109(3):325–334.
   PubMed Web of Science ®Google Scholar
• Brandi G, De Lorenzo S, Candela M, et al. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis. 2017;38(3):231–240.
   PubMed Web of Science ®Google Scholar
• Borrelli A, Bonelli P, Tuccillo FM, et al. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches. Redox Biol. 2018;15:467–479.
   PubMed Web of Science ®Google Scholar
• Tokushige K, Hashimoto E, Yatsuji S, et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45(9):960–967.
   PubMed Web of Science ®Google Scholar
• Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972–1978.
   PubMed Web of Science ®Google Scholar
• Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55(6):1809–1819.
   PubMed Web of Science ®Google Scholar
• Weinmann A, Alt Y, Koch S, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015;15(1):210.
   PubMed Web of Science ®Google Scholar
• Akram N, Imran M, Noreen M, et al. Oncogenic role of tumor viruses in humans. Viral Immunol. 2017;30(1):20–27.
   PubMed Web of Science ®Google Scholar
• Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9(1):64–70.
   PubMed Web of Science ®Google Scholar
• Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017;66(2):355–362.
   PubMed Web of Science ®Google Scholar
• De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345(8947):413–415.
   PubMed Web of Science ®Google Scholar
• Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124–131.e1.
   PubMed Web of Science ®Google Scholar
• Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49(3):851–859.
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Stål P, Wahlin S, et al. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int. 2019;39(6):1098–1108.
   PubMed Web of Science ®Google Scholar
• Vijay A, Elaffandi A, Khalaf H. Hepatocellular adenoma: an update. World J Hepatol. 2015;7(25):2603–2609.
   PubMed Web of Science ®Google Scholar
• Yoshioka Y, Hashimoto E, Yatsuji S, et al. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol. 2004;39(12):1215–1218.
   PubMed Web of Science ®Google Scholar
• van der Poorten D, Samer CF, Ramezani-Moghadam M, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology. 2013;57(6):2180–2188.
   PubMed Web of Science ®Google Scholar
• Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004;10(S2):S69–S73.
   PubMedGoogle Scholar
• Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001;7(9):797–801.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35(6):1485–1493.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
   PubMed Web of Science ®Google Scholar
• Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54(6):1244–1249.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13(3):594–601.e1.
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(6):1961–1971.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang J, Li Z, et al. Consumption of Sugar-Sweetened beverages has a Dose-Dependent effect on the risk of Non-Alcoholic fatty liver disease: an updated systematic review and Dose-Response Meta-Analysis. Int J Environ Res Public Health. 2019;16(12):2192.
   PubMed Web of Science ®Google Scholar
• Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48(6):993–999.
   PubMed Web of Science ®Google Scholar
• Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009;50(4):1094–1104.
   PubMed Web of Science ®Google Scholar
• Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: an update on diagnosis. Clujul Med. 2018;91(2):147–150.
   PubMedGoogle Scholar
• Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of Cause-Specific mortality in patients with advanced nonalcoholic fatty liver disease: a Multi-National cohort study. Gastroenterology. 2018;155(2):443–457.e17.
   PubMed Web of Science ®Google Scholar
• Ajmera V, Belt P, Wilson LA, et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol Hepatol. 2018;16(9):1511–1520.e5.
   PubMed Web of Science ®Google Scholar
• Bravi F, Bosetti C, Tavani A, et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1413–1421.e1.
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Wilkens LR, Lu SC, et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology. 2015;148(1):118–e15.
   PubMed Web of Science ®Google Scholar
• Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33(10):2156–2163.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through lifestyle modification significantly Reduces Features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378.e5.
   PubMed Web of Science ®Google Scholar
• Hannah WN, Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20(2):339–350.
   PubMed Web of Science ®Google Scholar
• Saran U, Guarino M, Rodríguez S, et al. Anti-tumoral effects of exercise on hepatocellular carcinoma growth. Hepatol Commun. 2018;2(5):607–620.
   PubMed Web of Science ®Google Scholar
• Bertot LC, Adams LA. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13(2):179–187.
   PubMed Web of Science ®Google Scholar
• Murff HJ, Roumie CL, Greevy RA, et al. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Cancer Cause Control. 2018;29(9):823–832.
   PubMed Web of Science ®Google Scholar
• Ma S, Zheng Y, Xiao Y, et al. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore). 2017;96(19):e6888.
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Singh AG, et al. Anti-Diabetic medications and the risk of hepatocellular cancer: a systematic review and Meta-Analysis. Am J Gastroenterol. 2013;108(6):881–891.
   PubMed Web of Science ®Google Scholar
• Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28(2):109–122.
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–332.
   PubMed Web of Science ®Google Scholar
• Lee TY, Wu JC, Yu SH, et al. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer. 2017;141(7):1307–1314.
   PubMed Web of Science ®Google Scholar
• Kim G, Jang S-Y, Nam CM, et al. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol. 2018;68(3):476–484.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang P, Martin RC, et al. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. Am J Cancer Res. 2016;6(5):1011–1025.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang YE, Chang JY, et al. An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. Am J Transl Res. 2016;8(11):4750–4763.
   PubMed Web of Science ®Google Scholar
• Sakai H, Shirakami Y, Shimizu M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol. 2016;22(1):394–406.
   PubMed Web of Science ®Google Scholar
• Zarrinpar A, Faltermeier CM, Agopian VG, et al. Metabolic factors affecting hepatocellular carcinoma in steatohepatitis. Liver Int. 2019;39(3):531–539.
   PubMed Web of Science ®Google Scholar
• Than NN, Ghazanfar A, Hodson J, et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM. 2017;110(2):73–81.
   PubMed Web of Science ®Google Scholar
• Sadler EM, Mehta N, Bhat M, et al. Liver transplantation for NASH-Related hepatocellular carcinoma versus Non-NASH Etiologies of hepatocellular carcinoma. Transplantation. 2018;102(4):640–647.
   PubMed Web of Science ®Google Scholar
• Wong CR, Njei B, Nguyen MH, et al. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;46(11–12):1061–1069.
   PubMed Web of Science ®Google Scholar